Important Announcement:

FAW Jiefang: In 2024, the total sales of trucks and buses will be 251,100 units, a year-on-year increase of 3.9

Junshi Biosciences: Deuterium hydrobromide deuterium hydrobromide tablets have been routinely approved by the National Medical Products Administration

Zhenhua shares: The general manager of the company received the notice of filing the case

Shanghai RAAS: The controlling shareholder increased its shareholding in the company and obtained a special loan commitment letter

Jucan Optoelectronics: The fund-raising project "annual output of 2.4 million pieces of red and yellow epitaxial wafers and chips" has been put into production

Important announcements of the Shanghai Stock Exchange:

*ST Kao: Withdraw the delisting risk alert and continue to implement other risk alerts

*ST Kao (603007) announced that the delisting risk warning situation touched by the company's reorganization has been eliminated, and the Shanghai Stock Exchange agreed to withdraw the delisting risk warning for the company's shares and continue to implement other risk warnings on January 10, 2025. The company's shares will be suspended for one day from the market open on January 13, 2025, and will resume trading from the market open on January 14, 2025. After the resumption of trading, the abbreviation of the company's A shares will be changed to "ST Kao", the stock code will remain 603007, and the daily rise and fall limit of the stock price will remain 5%.

Liba shares: Song Jianrui, chairman and general manager of the company, resigned

Liba shares (603519) announcement: due to family reasons, Song Jianrui applied for resignation from the company's chairman (legal representative) and general manager, and at the same time resigned from the relevant positions of the board of directors strategy committee and nomination committee, and will no longer hold any position in the company after resignation. As of the date of disclosure of this report, Song Jianrui did not directly or indirectly hold shares of the company.

*ST Information and Communication: The company's shares are superimposed on the delisting risk warning

*ST Information and Communications (600289) announcement: Because the company has not completed the correction of capital occupation within 2 months of suspension (the expiration date of the suspension on January 10, 2025), according to the relevant provisions of the "Shanghai Stock Exchange Stock Listing Rules", the company is expected to resume trading on January 14, 2025, and will be superimposed on the implementation of delisting risk warning. If the company fails to complete the correction within 2 months after the delisting risk warning is superimposed, the company's shares will be terminated from listing.

Junshi Biosciences: Deuterium hydrobromide deuterium hydrobromide tablets have been routinely approved by the National Medical Products Administration

Junshi Biosciences (688180) announced that its holding subsidiary, Shanghai Wangshi Biomedical Technology Co., Ltd., received the "Notice of Approval of Drug Supplement Application" approved and issued by the State Food and Drug Administration, and the indication of deuterium hydrobromide deuterium hydrobromide tablets (trade name: Mindwei, product code: VV116/JT001) for the treatment of adult patients with mild to moderate novel coronavirus infection (hereinafter referred to as "COVID-19") was approved by the State Food and Drug Administration, and the approval was changed from conditional approval to routine approval.

Zhenhua shares: The general manager of the company received the notice of filing the case

Zhenhua shares (603067) announcement: Ke Yusheng, general manager of the company, received the "Notice of Case Filing from the China Securities Regulatory Commission" on January 10, 2025, and the CSRC decided to file a case against him for suspected short-term trading of Zhenhua shares. This matter is an investigation of Ke Yusheng personally, and will not have a significant impact on the operation of the company's board of directors and the company's daily business activities, and Ke Yusheng will actively cooperate with the investigation.

Hengrui Pharmaceutical: Relcalimab for injection obtained the drug registration certificate

Hengrui Pharmaceutical (600276) announced: Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received the "Drug Registration Certificate" approved by the State Food and Drug Administration to issue relcarcimab for injection, which is the company's first Class 1 innovative drug marketed in the field of cardiovascular diseases.

Important announcements of the Shenzhen Stock Exchange:

Shenglan shares: The application for issuing convertible corporate bonds to unspecified objects was accepted by the Shenzhen Stock Exchange

Shenglan shares (300843) announcement: the company received the "Notice on Accepting the Application Documents for the Issuance of Convertible Corporate Bonds by Shenglan Technology Co., Ltd. to Unspecified Objects" issued by the Shenzhen Stock Exchange on January 11. The Shenzhen Stock Exchange checked the application documents submitted by the company for the issuance of convertible corporate bonds to unspecified objects, considered the application documents complete, and decided to accept them.

Jucan Optoelectronics: The fund-raising project "annual output of 2.4 million pieces of red and yellow epitaxial wafers and chips" has been put into production

Jucan Optoelectronics (300708) announced: the company's fund-raising investment project "annual output of 2.4 million pieces of red and yellow epitaxial wafers and chips" has now met the conditions for production. The commissioning of this fundraising project marks a significant increase in the company's product categories, stronger product service capabilities, and the company's official transformation into a full-color LED chip supplier.

Julun Intelligence: Robot-related business income has a limited impact on the company's short-term performance

Julun Intelligent (002031) announcement: The company is concerned that some media have listed the company as a "robot concept" related stock, and as of the disclosure date of this announcement, the relevant business income has a limited impact on the company's short-term performance. Investors are advised to invest rationally and pay attention to risks.

Shanghai RAAS: The controlling shareholder increased its shareholding in the company and obtained a special loan commitment letter

Shanghai RAAS (002252) announcement: Recently, the company received a notice from the controlling shareholder Haiyingkang that Haiyingkang obtained the "Agricultural Bank of China Loan Commitment Letter" issued by the Qingdao Branch of Agricultural Bank of China Co., Ltd. (hereinafter referred to as "Agricultural Bank of China"), and the Agricultural Bank of China agreed to provide loan support for Haiyingkang, with a loan amount of 450 million yuan and a loan term of 3 years.

FAW Jiefang: In 2024, the total sales of trucks and buses will be 251,100 units, a year-on-year increase of 3.9

FAW Jiefang (000800) announcement: The company released the 2024 annual production and sales report, and the total output of trucks and buses in 2024 will be 248,700, a year-on-year decrease of 0.79%; Total sales were 251,100 units, up 3.9% year-on-year.

Yue Hongyuan A: There may be a risk of a short-term increase and then a decline

Yue Hongyuan A (000573) announcement: The short-term increase in the company's stock price is significantly higher than that of the Shenzhen Stock Exchange A Index, and there is a situation where market sentiment is overheated, and there may be a risk of falling after a large short-term increase. Recently, there have been no major changes in the company's operation, and there is no material information that should be disclosed but not disclosed, so investors are requested to pay attention to the risks of secondary market transactions, make rational decisions, and invest prudently.